logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

EHA 2019 – Induction with obinutuzumab plus DHAP in mantle cell lymphoma leads to a high level of minimal residual disease negativity

In the LYMA-101 trial, 75% of previously untreated patients reached the minimal residual disease negativity after this regimen, without major toxicity